Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 235-237

  Dimopoulos, Meletios A ^a   Terpos, Evangelos ^a   Kastritis, Efstathios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Akt; Bortezomib; Carfilzomib; mTOR; Proteasome

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EVEROLIMUS; OPROZOMIB; PERIFOSINE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A;

CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); REMISSION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; HUMANS; PROTEASOME INHIBITORS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84877605848     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.02.014     Document Type: Conference Paper

References (21)

1. P. Moreau, P.G. Richardson, M. Cavo Proteasome inhibitors in multiple myeloma: 10 years later Blood 120 2012 947 959
2. A.M. Roccaro, X. Leleu, A. Sacco Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia Blood 111 2008 4752 4763
3. X. Leleu, L. Xu, X. Jia Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia Blood 113 2009 626 634
4. X. Leleu, J. Eeckhoute, X. Jia Targeting NF-kappaB in Waldenstrom macroglobulinemia Blood 111 2008 5068 5077
5. A.M. Roccaro, A. Sacco, M. Aujay Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia Blood 115 2010 4051 4060
6. S.V. Rajkumar, P.G. Richardson, T. Hideshima Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 2005 630 639 (Pubitemid 46224241)
7. M. Wang, X.H. Han, L. Zhang Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo Leukemia 22 2008 179 185
8. L. Alinari, V.L. White, C.T. Earl Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma MAbs 1 2009 31 40
9. A.M. Roccaro, A. Sacco, X. Jia Mechanisms of activity of the TORC1 inhibitor everolimus in Waldesntrom's macroglobulinemia Clin Cancer Res 18 2012 6609 6622
10. A. Sacco, M. Aujay, B. Morgan Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia Clin Cancer Res 17 2011 1753 1764
11. A.M. Roccaro, A. Sacco, M. Aujay Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia Blood 115 2010 4051 4060
12. M.A. Dimopoulos, A. Anagnostopoulos, M.C. Kyrtsonis Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib Haematologica 90 2005 1655 1658 (Pubitemid 41814990)
13. S.P. Treon, Z.R. Hunter, J. Matous Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG trial 03-248 Clin Cancer Res 13 2007 3320 3325 (Pubitemid 46944918)
14. C.I. Chen, C.T. Kouroukis, D. White Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1570 1575 (Pubitemid 46733084)
15. I.M. Ghobrial, F. Hong, S. Padmanabhan Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia J Clin Oncol 28 2010 1422 1428
16. I.M. Ghobrial, W. Xie, S. Padmanabhan Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia Am J Hematol 85 2010 670 674
17. S.P. Treon, L. Ioakimidis, J.D. Soumerai Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 J Clin Oncol 27 2009 3830 3835
18. M.A. Dimopoulos, R. Garcia-Sanz, M. Gavriatopoulou Primary therapy of Waldenstrom's macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone and rituximab (BDR): a phase II study of the European myeloma network ASH Annual Meeting Abstracts 116 2010 1941 2010
19. J.J. Shah, R.Z. Orlowski Proteasome inhibitors in the treatment of multiple myeloma Leukemia 23 2009 1964 1979
20. Treon SP, Tripsas CK, Sheehy P, et al. Prospective phase II clinical trial of Carfilzomib, Rituximab and Dexamethasone (CARD) in patients with symptomatic Waldenström's Macroglobulinemia (WM). IMWWM 7 Newport, August 2012.
21. M.A. Dimopoulos, M.A. Gertz, E. Kastritis Update on treatment recommendations from the fourth International workshop on Waldenstrom's macroglobulinemia J Clin Oncol 27 2009 120 126